Multicenter, Double-blind, and Randomized Controlled Trial of Ultra-Distal TENS Device for Migrai… (NCT07451158) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Multicenter, Double-blind, and Randomized Controlled Trial of Ultra-Distal TENS Device for Migraine Treatment
China206 participantsStarted 2025-11-15
Plain-language summary
Multicenter, double-blind, and randomized controlled trial of Ultra-Distal Transcutaneous Electrical Nerve Stimulation (TENS) Device for Migraine treatment.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female, aged between 18 and 75;
* According to the diagnostic criteria of the International Classification of Headache Disorders (ICHD-III), the diagnosis is episodic migraine with or without aura or probable migraine with or without aura;
* The duration of the illness is at least 12 months;
* The age of onset of the first migraine is less than 50 years old;
* During the screening period of 4 weeks, there were 2-8 episodes of headache, with moderate or severe pain intensity;
* Before screening, the subjects should provide their previous medical records as much as possible;
* Participants can distinguish migraines from other conditions, including tension-type headaches and cluster headaches
* Understand and adhere to the research procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing;
Exclusion Criteria:
* Pregnant and lactating women;
* Suffering from arrhythmia or other heart diseases (such as ischemic heart disease, coronary artery spasm, myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, angina pectoris);
* Have undergone surgery within the past 6 months;
* Recent stroke or transient ischemic attack;
* Equipped with a pacemaker;
* History of previous seizures;
* Metal implants in the head;
* Patients with clinical evidence of brain damage;
* Chronic pain associated with other diseases;
* Use antipsychotic drugs;
* Those who are intolerant to neuroregulato…
What they're measuring
1
Reduce the intensity of migraine
Timeframe: Baseline and 2 hours post-treatment
2
the pre-selected accompanying symptoms
Timeframe: Baseline and 2 hours post-treatment
Trial details
NCT IDNCT07451158
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University